Who Owns Biologics by McKesson?
Biologics by McKesson is owned by McKesson Corporation, a publicly traded American healthcare company headquartered in Irving, Texas. Biologics by McKesson operates as a wholly-owned specialty pharmacy subsidiary of McKesson, specializing in oncology and rare disease medications with over 30 years of experience serving cancer patients and individuals with complex conditions.
Parent Company
McKesson Corporation
Founded
1994
Status
Publicly Traded
Headquarters
Cary, North Carolina, USA
Who Owns Biologics by McKesson?
- Parent Company: McKesson Corporation
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: NYSE: MCK
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Biologics by McKesson | McKesson Corporation | Wholly owned |
History of Biologics by McKesson
- Founded: 1994
- Founders: McKesson Corporation (internal development)
Biologics by McKesson was founded in 1994 as an independent specialty pharmacy focused on serving cancer patients and individuals with complex medical conditions. The company was established to address the unique needs of patients requiring specialized medications and personalized care support. This founding vision demonstrated exceptional insight into the growing need for specialized pharmacy services that could provide comprehensive support for patients with complex treatment regimens, particularly those undergoing cancer therapy and dealing with rare diseases.
Throughout the late 1990s and 2000s, Biologics by McKesson expanded its capabilities and patient base, becoming recognized as a leader in specialty pharmacy services for oncology. The company developed comprehensive patient support programs including medication adherence support, side effect management, and access assistance. This period of growth demonstrated Biologics by McKesson's ability to build a specialized service model that could address the complex needs of cancer patients while establishing strong relationships with healthcare providers and pharmaceutical manufacturers.
In 2019, Biologics by McKesson expanded its specialty pharmacy capabilities through new exclusive distribution agreements, strengthening its position in oncology and complex disease management. The company has continued to grow its network of specialty pharmacists and clinical support staff. This strategic expansion demonstrated Biologics by McKesson's ability to leverage its clinical expertise and market position to secure exclusive partnerships that could enhance its service offerings and expand access to specialized medications for patients.
In recent years, Biologics by McKesson has focused on advancing cancer care through collaboration with pharmaceutical manufacturers, healthcare providers, and patient advocacy organizations. The company serves over 1.6 million patients annually and maintains partnerships with over 200 pharmaceutical manufacturers. This continued growth and collaboration demonstrate Biologics by McKesson's ability to maintain its leadership position in specialty pharmacy while adapting to the evolving needs of cancer patients and the changing landscape of oncology treatments and personalized medicine.
About McKesson Corporation
What does McKesson do?
McKesson distributes pharmaceutical products, including brand-name drugs, generic drugs, and specialty medications, to pharmacies, hospitals, physician offices, and other healthcare providers across the United States and Canada. The company also operates the US Oncology Network, distributes medical-surgical supplies, and provides technology solutions to biopharma manufacturers through its Prescription Technology Solutions segment.
Is McKesson publicly traded?
Yes, McKesson Corporation trades on the New York Stock Exchange under ticker symbol MCK. The company has no controlling shareholder, with ownership distributed among institutional investors including Vanguard Group and BlackRock.
What is McKesson's annual revenue?
In fiscal year 2024 (ended March 31, 2024), McKesson reported revenue of approximately $308.9 billion, a 10% increase from the prior fiscal year. The U.S. Pharmaceutical segment accounted for approximately $275 billion of total revenue.
Who is McKesson's CEO?
Brian Tyler has served as Chief Executive Officer of McKesson since April 2019, succeeding John Hammergren. Tyler has led the company's strategic focus on oncology and biopharma services as higher-growth businesses within the healthcare distribution ecosystem.
When was McKesson founded?
McKesson was founded in 1833 by John McKesson and Charles Olcott in New York City as Olcott & McKesson, making it one of the oldest continuously operating companies in the United States.
What is McKesson's role in the opioid settlement?
McKesson, along with Cencora and Cardinal Health, reached a $21 billion settlement with U.S. states and local governments in 2022 to resolve claims that the three distributors failed to adequately monitor suspicious opioid orders. McKesson's share of the settlement is approximately $7.9 billion, to be paid over 18 years.
- Founded: 1833
- Headquarters: Irving, Texas, USA
- Company Type: Publicly Traded
- Stock: NYSE: MCK
Where Is Biologics by McKesson Made / Based?
- Headquarters: Cary, North Carolina, USA
- Manufacturing / Operations: United States
Brands Owned by McKesson Corporation
- Health Mart - Independent pharmacy franchise network with over 4,500 member pharmacies across ...
- McKesson Medical-Surgical - Medical supplies and equipment distribution brand providing healthcare products ...
- McKesson Provider Technologies - Healthcare IT and software solutions provider offering electronic health records...
Biologics by McKesson Ownership: Pros & Cons
Advantages
- +Access to McKesson's extensive pharmaceutical distribution network and supply chain
- +Clinical expertise and specialized pharmacist support for oncology and rare diseases
- +Comprehensive patient support programs including adherence and side effect management
- +Partnerships with major pharmaceutical manufacturers and healthcare providers
- +Advanced technology platforms for medication management and patient communication
- +Significant scale enabling access to specialty medications and biologics
Considerations
- -Dependency on McKesson's supply chain and corporate policies
- -Regulatory oversight of specialty pharmacy operations and controlled substances
- -Competition from other specialty pharmacies and integrated healthcare systems
- -Complex insurance and reimbursement requirements for specialty medications
- -Pressure on specialty pharmacy margins from PBM contracting
- -Limited flexibility in certain operational decisions due to corporate structure
Frequently Asked Questions About Biologics by McKesson
Where to Buy
Disclosure: We may earn commission from purchases
Biologics by McKesson on AmazonCompetitors to Biologics by McKesson
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Takeda | Japan | 2011 | Mass Market | Asia Pacific | All Genders | |
| Novartis | Switzerland | 2009 | Mass Market | Global | All Genders | |
| Cardinal Health | USA | 2014 | Mass Market | North America | Male | |
| Cardinal Health | USA | 2010 | Mass Market | North America | All Genders | |
| Cvs Health | USA | 1982 | Mass Market | North America | All Genders | |
| Sanofi | France | 2002 | Mass Market | Europe | All Genders |
Learn More About Competitors
Adcetris
Owned by Takeda Pharmaceutical Company
Prescription antibody-drug conjugate for treating Hodgkin lymphoma and other CD30-positive lymphomas, manufactured and marketed by Takeda Pharmaceutical Company.
Afinitor
Owned by Novartis
Prescription oncology medication for treating various cancers including renal cell carcinoma and breast cancer, manufactured and marketed by Novartis.
Cardinal Health At-Home
Owned by Cardinal Health
At-home healthcare solutions provider delivering medical supplies, equipment, and pharmacy services directly to patients' homes owned by Cardinal Health.
Cardinal Health Specialty Pharmacy
Owned by Cardinal Health
Specialty pharmaceutical distribution and services provider serving specialty pharmacies, hospitals, and healthcare providers with complex medications owned by Cardinal Health.
Coram
Owned by CVS Health
American specialty pharmacy and infusion services provider offering home and alternate site care, owned by CVS Health.
Eloxatin
Owned by Sanofi
Prescription chemotherapy medication for treating colorectal cancer, manufactured and marketed by Sanofi.
Competitive Analysis
Market Positioning: Biologics by McKesson competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
McKesson Corporation Stock Information
Jobs at McKesson Corporation
Latest News About Biologics by McKesson
Related Articles About Biologics by McKesson
View more articles
Monthly M&A Roundup: February 2026 Brand Ownership Changes
From Keurig Dr Pepper's planned split to the Netflix-WBD saga, here is every major brand ownership change and deal in February 2026.
The Most Acquired Categories: Tech vs CPG vs Pharma
Which industries see the most brand acquisitions? We compared technology, consumer goods, and pharmaceuticals to find out where the most M&A activity happens and why.
The Truth About 'Made in America' Brand Claims
Many brands market themselves as American-made. But what does that actually mean when the parent company is foreign, the parts come from overseas, and 'assembled in USA' is not the same as 'made in USA'?
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Activase
Prescription thrombolytic medication for treating acute myocardial infarction and stroke, manufactured and marketed by Roche.
Acuvue
American brand of contact lenses and vision care products specializing in daily disposable and extended wear contact lenses, manufactured and marketed by Johnson & Johnson.
Adcetris
Prescription antibody-drug conjugate for treating Hodgkin lymphoma and other CD30-positive lymphomas, manufactured and marketed by Takeda Pharmaceutical Company.